Stereoselective Synthesis of a Novel Apio Analogue of Neplanocin A as Potential *S*-Adenosylhomocysteine Hydrolase Inhibitor

Hyung Ryong Moon,[†] Hea Ok Kim,[‡] Kang Man Lee,[†] Moon Woo Chun,[§] Joong Hyup Kim,^{||} and Lak Shin Jeong^{*,†}

College of Pharmacy, Ewha Womans University, Seoul 120-750, Korea, Division of Chemistry and Molecular Engineering and College of Pharmacy, Seoul National University, Seoul 151-742, Korea, and Korea Institute of Science and Technology, Seoul 136-791, Korea


lakjeong@ewha.ac.kr

Received July 28, 2002

ORGANIC LETTERS 2002

Vol. 4, No. 20 3501-3503

ABSTRACT



A total synthesis of apio-neplanocin A, which combines properties of apio nucleoside and neplanocin A and is a potential inhibitor of S-adenosylhomocysteine hydrolase, was accomplished starting from D-ribose via stereoselective hydroxymethylation and RCM reaction.

S-Adenosylhomocysteine hydrolase (SAH) catalyzes the interconversion of *S*-adenosylhomocysteine into adenosine and L-homocysteine.¹ Inhibition of this enzyme accumulates *S*-adenosylhomocysteine in the cell, which in turn inhibits *S*-adenosylmethionine-dependent transmethylation reaction.¹ Such transmethylation is essential for viral *m*RNA maturation and thus plays a crucial role in viral replication. Since a close correlation between SAH inhibitors and their antiviral activity has been found, SAH has been a promising target for the development of antiviral agents.^{2–4} Neplanocin A (1)⁵ is a natural carbocyclic nucleoside and one of the most potent

inhibitors of SAH.⁶ It belongs to the type-I mechanism-based inhibitors,³ in which 3'-hydroxyl group of compound **1** is oxidized by NAD⁺ to the 3'-keto derivative, resulting in the depletion of the cofactor NAD⁺. In correlation with neplanocin A's strong inhibition of SAH, it also exhibits strong antiviral activity against DNA viruses as well as RNA viruses.⁷

Recently, the major trend in developing new antiviral agents has been shifted to the development of unique nucleosides with an unnatural sugar moiety. Discovery of L- β -1,3-oxathiolanyl cytosine (3TC, lamivudine)⁸ as an anti-

[†] Ewha Womans University.

[‡] Division of Chemistry and Molecular Engineering, Seoul National University.

[§] College of Pharmacy, Seoul National University.

Korea Institute of Science and Technology

^{(1) (}a) Ueland, P. M. *Pharmacol. Rev.* **1982**, *34*, 223. (b) Palmer, J. L.; Abeles, R. H. *J. Biol. Chem.* **1979**, *254*, 1217.

⁽²⁾ De Clercq, E. Biochem. Pharmacol. 1987, 36, 2567.

⁽³⁾ Wolfe, M. S.; Borchardt, R. T. J. Med. Chem. 1991, 34, 1521

^{(4) (}a) De Clercq, E. *Nucleosides Nucleotides* **1994**, *13*, 1271. (b) De Clercq, E. *Nucleosides Nucleotides* **1998**, *17*, 625. (c) Cools, M.; De Clercq, E. Biochem. Pharmacol. **1989**, *38*, 1061.

^{(5) (}a) Yaginuma, S.; Muto, N.; Tsujino, M.; Sudate, Y.; Hayashi, M.; Otani, M. J. Antibiot. (Tokyo) **1981**, 34, 359. (b) Hayashi, M.; Yaginuma, S.; Yoshioka, H.; Nakatsu, K. J. Antibiot. (Tokyo) **1981**, 34, 675.

⁽⁶⁾ Borchardt, R. T.; Keller, B. T.; Patel-Thombre, U. J. Biol. Chem. 1984, 259, 4353.

⁽⁷⁾ De Clercq, E. Antimicrob. Agents Chemother. 1985, 28, 84.

hepatitis B virus (HBV) drug gave an impetus to the research in this class of compounds. Apio nucleoside also belongs to this unique group, in that the 4'-hydroxymethyl group of the normal sugar is moved to the C3'-position.⁹ One of them, apio-ddA (2) has been reported to show potent anti-HIV activity comparable to that of the parent 2',3'-dideoxyadenosine (ddA) and better stability against glycosidic bond hydrolysis than that of ddA.⁹

On the basis of these findings, it was of great interest to synthesize novel apio-neplanocin A (3) and evaluate its inhibitory effect on SAH (Figure 1). This molecule combines






Figure 1. Rationale for the design of apio-neplanocin A (3).

the properties of **1** and **2**. To the best of our knowledge, compound **3** is the first example of an apio carbocyclic nucleoside with unnatural five-membered carbocycles. In this communication, we report the stereoselective synthesis of enantiomerically pure apio-neplanocin A (**3**), starting from D-ribose via ring-closing metathesis (RCM)¹⁰ and stereoselective hydroxymethylation at the C3'-position and its inhibitory activity against SAH.


Retrosynthetic analysis (Scheme 1) shows that the desired nucleoside **3** can be synthesized from the glycosyl donor, cyclopentenol **I**, which is derived from RCM reaction of diene **II**. Compound **II** can be prepared from lactol **III** via





stereoselective hydroxymethylation and Wittig reaction. Lactol **III** can be derived from D-ribose using Grignard reaction and oxidative cleavage.

Synthesis of the glycosyl donor **11** is shown in Scheme 2. D-Ribose was reacted with acetone and catalytic amounts




^{*a*} Reagents: (a) acetone, c-H₂SO₄, rt, 2.5 h; (b) CH₂=CHMgBr, THF, from -78 to 0 °C, 3 h; (c) NaIO₄, CH₂Cl₂, H₂O, from 0 °C to rt, 40 min; (d) K₂CO₃, 37% CH₂O, MeOH, 80 °C, 36 h; (e) Ph₃PCH₃Br, KO*t*-Bu, THF, rt, 15 h; (f) Grubbs catalyst (second generation), CH₂Cl₂, rt, 2 h; (g) TrCl, DMAP, pyridine, rt, 20 h; (h) MsCl, NEt₃, CH₂Cl₂, rt, 2 h.

of sulfuric acid to give 2,3-acetonide 4. Treatment of 4 with vinylmagnesium bromide in THF afforded the triol 5 stereoselectively.¹¹ Oxidative cleavage of 5 with sodium metaperiodate gave the lactol 6 in excellent yield. Compound 6 was subjected to the aldol condensation¹² to give the

^{(8) (}a) Beach, J. W.; Jeong, L. S.; Alves, A. J.; Pohl, D.; Kim, H. O.; Chang, C. N.; Doong, S. L.; Schinazi, R. F.; Cheng, Y.-C.; Chu, C. K. J. Org. Chem. **1992**, 57, 2217. (b) Coates, J. A. V.; Cammack, N.; Jenkinson, H. J.; Mutton, I. M.; Pearson, B. A.; Storer, R.; Cameron, J. M.; Penn, C. R. Antimicrob. Agents Chemother. **1992**, 36, 202. (c) Soudeyns, H.; Yao, X.-J.; Gao, Q.; Belleau, B.; Kraus, J.-L.; Nguyen-Ba, N.; Spira, B.; Wainberg, M. A. Antimicrob. Agents Chemother. **1991**, 35, 1386.

^{(9) (}a) Sells, T. B.; Nair, V. *Tetrahedron Lett.* **1993**, *34*, 3527. (b) Terao,
Y.; Akamatsu, M.; Achiwa, K. *Chem. Pharm. Bull.* **1991**, *39*, 823. (10) Grubbs, R. H.; Chang, S. *Tetrahedron* **1998**, *54*, 4413.


hydroxymethyl derivative 7 (95%) stereoselectively. The stereoselective formation of 7 in the mixed aldol condensation may be mechanistically explained as illustrated in Scheme 3. Treatment of 6 with K_2CO_3 followed by the



addition of 37% formaldehyde might produce two possible adducts, *trans*-**7a** and *cis*-**7a**, via the resulting enolate **6a**. Under equilibrium, *trans*-**7a** was not converted to a lactol due to high ring strain but underwent the reverse aldol reaction, going back to the enolate **6a**, while *cis*-**7a** was smoothly cyclized to form the thermodynamically stable lactol **7**. Thus, under the reaction conditions, compound **7** was formed as the sole product.

Wittig reaction of **7** with methyl triphenylphosphonium ylide gave the diene **8** as a single stereoisomer, which was ready for RCM.¹⁰ Diene **8** was treated with second generation Grubbs catalyst in methylene chloride to give the cyclopentenol **9** with desired stereochemistry in almost exclusive yield. The primary hydroxyl group of **9** was selectively protected with a trityl group to give **10**, which was converted to the mesylate **11** for use in condensation reaction.

Synthesis of the desired nucleoside **3** is illustrated in Scheme 4. Condensation of **11** with adenine anion in the presence of 18-crown-6 afforded the desired N-9 isomer **12** (61%) as a major product with concomitant minor formation of N-7 isomer **13** (9%). Regioisomers N-9 [UV (MeOH) λ_{max} 260 nm] and N-7 [UV (MeOH) λ_{max} 279 nm] were easily differentiated by comparison of literature UV data.¹³ The desired isomer **12** was treated with 66% aqueous trifluoroacetic acid to give the final nucleoside **3**.



 a Reagents: (a) adenine, K2CO3, 18-crown-6, DMF, 80 °C, 12 h; (b) 66% aqueous CF3CO2H, THF, rt, 3 days.

The inhibitory activity of the final nucleoside **3** against human recombinant SAH was measured. Unlike neplanocin A, compound **3** did not exhibit significant inhibitory activity against SAH, although we expected tight binding of **3** to SAH. This lack of enzyme inhibitory activity might be due to the presence of the tertiary hydroxyl group at the C3'position, which cannot be oxidized by cofactor-bound NAD⁺. Antiviral assays against DNA and RNA viruses and structure– activity relationship studies are in progress in our laboratory and will be reported in due course.

In summary, a novel apio analogue 3 of neplanocin A, combining the structural characteristics of apio nucleoside and neplanocin A, was synthesized starting from D-ribose. The synthetic procedure is highlighted by stereoselective hydroxymethylation and RCM reaction. Apio-neplanocin A (3) is believed to be the first example of a carba nucleoside with an unnatural apio carbocycle.

Acknowledgment. This work was supported by Korea Research Foundation (Grant KRF-2001-005-F00022).

Supporting Information Available: Complete experimental procedures and characterization data. This material is available free of charge via the Internet at http://pubs.acs.org.

OL026624M

⁽¹¹⁾ Shing, T. K. M.; Elsley, D. A.; Gillhouley, J. G. J. Chem. Soc., Chem. Commun. 1989, 1280.

⁽¹²⁾ Ho, P.-T. Tetrahedron Lett. 1978, 19, 1623.

^{(13) (}a) Panzica, R. P.; Rousseau, R. J.; Robins, R. K.; Townsend, L. B. J. Am. Chem. Soc. **1972**, 94, 4708. (b) Rousseau, R. J.; Robins, R. K.; Townsend, L. B. J. Am. Chem. Soc. **1968**, 90, 2661.